---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-046064"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:19:01.672614+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences reports $86.5M net loss for 2024; cash runway through 2027; three INDs cleared

## Summary
- Cash, equivalents, and marketable securities $341.4M at YE 2024 (up from $203.5M), providing runway through at least 2027.
- Full-year 2024 net loss $86.5M vs $69.1M in 2023; R&D expenses $80.1M vs $62.5M.
- TYRA-300 showed 54.5% confirmed PR (6/11) at ≥90mg QD in FGFR3+ mUC patients (SURF301).
- Three INDs cleared: TYRA-300 Phase 2 for NMIBC (SURF302) and ACH (BEACH301), and TYRA-430 Phase 1 (SURF431).
- First patient dosing expected Q2 2025 for BEACH301 (achondroplasia), SURF302 (NMIBC), and SURF431 (HCC).

## SEC filing metadata
- accession: 0000950170-25-046064
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000095017025046064/0000950170-25-046064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000095017025046064/tyra-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-046064
- JSON: https://secwatch.observer/filing/0000950170-25-046064.json
- Plain text: https://secwatch.observer/filing/0000950170-25-046064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.